Quick Links
Breast Cancer Links
- Breast Cancer Overview
- Breast Cancer Resources
- IHC Atlas
- Clinical Case Reviews
- Spotlight Series
- Knowledge Check
Gastric Cancer Links
Subscribe today to ensure you never miss crucial information!
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; mNSCLC, metastatic non-small cell lung cancer; NCCN, National Comprehensive Cancer Network.
1. CAP. Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. Version: 1.6.0.0. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.7.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 10, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. CAP. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of Gynecologic Origin. Version 1.2.0.0. Available at: https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates. Accessed: February 2025.
HER2 IHC testing is critical for guiding clinical decisions in breast, gastric, and other solid tumors.1,2 With evolving clinical advancements, ensuring scoring consistency across the full spectrum of HER2 expression is more important than ever.2
Explore real-world cases, assessment tools, and expert-developed resources to enhance your HER2 IHC scoring confidence.
Examine real-world staining patterns across 100+ expert-selected cases to support scoring accuracy and diagnostic consistency in your practice.
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
1. Ko HC, et al. Front Oncol 2025;15:1565872. doi: 10.3389/fonc.2025.1565872. 2. Zhang H, et al. Histopathology 2024;85(1):3-19.
1. Ko HC, et al. Front Oncol 2025;15:1565872. doi: 10.3389/fonc.2025.1565872. 2. Zhang H, et al. Histopathology 2024;85(1):3-19.
This website is intended to help healthcare professionals practicing in the United States find and access scientifically balanced, evidence-based, and peer-led information and professional resources in support of HER2 IHC evaluation. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This information is provided for educational purposes only. It is not intended for use in the diagnosis or treatment of individual patients. Are you a healthcare professional practicing in the United States?
I am a Daiichi Sankyo Company or AstraZeneca authorized person
This website is only intended for healthcare professionals practicing in the United States and authorized Daiichi Sankyo Company or AstraZeneca personnel. US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. This website is not intended for use by US Field Sales personnel. None of the content of this site should be directly linked or distributed without approval.